Combining pioneering iPSC technology and patented live cell bioimaging, LumiSTAR is opening up exciting new possibilities in the treatment of various diseases and the development of innovative new dru ...

Century Therapeutics, Inc. (NASDAQ: IPSC) announced that its management team will host a live fireside chat on Tuesday, April 22, 2025, at 10:00 a.m. EDT to discuss ...

Century Therapeutics, Inc. (IPSC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

SUZHOU, China, April 15, 2025 /PRNewswire/ --In January 2025 (U.S. time), the U.S. Food and Drug Administration (FDA) officially approved the Investigational New Drug (IND) application submitted ...

The partners will use Cellino's autonomous biomanufacturing tech to produce high-quality autologous iPSCs for Karis' cardiovascular therapy.

Cellistic introduces Echo-NK Platform to enable scalable manufacturing of allogeneic cell therapies to target multiple diseases: Mont-Saint-Guibert, Belgium Monday, April 14, 2025 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cellistic has launched the Echo-NK platform to enable the scalable manufacturing of allogeneic cell therapies to target ...

Co. Ltd. has announced IND clearances by the FDA for its XS-411 and XS-228 cell therapies, for Parkinson’s disease and amyotrophic lateral sclerosis (ALS), respectively.

The partnership aims to industrialize the world’s first clinical-stage autologous induced pluripotent stem cell (iPSC)-derived cell therapy for peripheral artery disease (PAD) and coronary ...

Carbon-negative regenerative supply chains with focus on local procurement to lower cost burden in times of high tariffs and ...